Agulnick et al. [47] demonstrated that insulin-producing endocrine cells differentiated in vitro from human embryonic stem cells could function in macroencapsulation devices in vivo, highlighting the potential of stem cell-derived islets as a viable treatment option for type 1 diabetes. This evidence concerns the gene INS and type 1 diabetes mellitus.